Merck (MRK) reported second-quarter results that topped Wall Street expectations, driven by continued strength in its blockbuster cancer drug Keytruda, as well as strong uptake for newer drugs like Winrevair.

The drugmaker posted an adjusted loss of $0.13 per share, beating estimates